Budgetary Impact of Accelerating COVID-19 Vaccination

IntroductionCognitive and functional deterioration is common in hospital setting and occurs in 40 percent of admitted older patients. One of its main causes is physical inactivity. The objective of our health technology assessment was to assess the safety and clinical effectiveness of a structured multicomponent intervention of physical exercise (Vivifrail) for the prevention of the cognitive and functional deterioration in hospitalized patients aged 70 years or older and to estimate costs and the budgetary impact for the Spanish National Health Service.MethodsA systematic review of available scientific literature (including experimental and observational designs) on the safety and effectiveness of Vivifrail was performed. A costing study and budgetary impact analysis of the incorporation of Vivifrail as a therapeutic alternative to standard care with a time horizon of 5 years was performed.ResultsOne randomized controlled trial (RCT) (n = 370) showed positive effects of Vivifrail compared to usual care in functional capacity (mean difference (MD) = 2.20, 95% confidence interval (CI) 1.78 to 2.62), cognitive state (MD = 1.80, 95% CI 1.24 to 2.36), and quality of life (MD = 13.20, 95% CI 12.70 to 13.70). Regarding other variables, the Vivifrail increased the grip strength of the dominant hand (MD = 2.30; 95% CI = 1.79 to 2.81), verbal fluency (MD = 2.15; 95% CI = 1.56 to 2.74), performance of double tasks (MD = 0.10; 95% CI = 0.07 to 0.13), executive function (MD = −31.07; 95% CI = −49.23 to −12.91) and emotional state (MD = −2.00; 95% CI = −2.50 to −1.50).The total cost of implementing Vivifrail in a 1,000-bed general hospital would be EUR18,000 per year (adjusted to 2020 currency), with approximately 150 patients older than 75 years benefited. This represents a cost of EUR120 per patient.ConclusionsThe Vivifrail could improve functional and cognitive capacity, although available evidence on the Vivifrail is very scarce. More well designed and executed RCT and cost-effectiveness study confirming or refuting the promising findings are needed for a new assessment.

Download Full-text

The Financial and Budgetary Impact of Enlargement and Accession

EU Enlargement : A Legal Approach ◽

10.5040/9781472563026.ch-007 ◽

2014 ◽

Cited By ~ 2

Keyword(s):

Budgetary Impact

Download Full-text

The Budgetary Impact of Defense Expenditures in the Middle East and South Asia

Economic Causes and Consequences of Defense Expenditures in the Middle East and South Asia ◽

10.4324/9780429041273-7 ◽

2019 ◽

pp. 101-132

Author(s):

Robert E. Looney ◽

David Winterford

Keyword(s):

Middle East ◽

South Asia ◽

Budgetary Impact

Download Full-text

THE BUDGETARY IMPACT OF PRIVATISATION*

Routledge Studies in the Modern World Economy - Fiscal Policy and Economic Reforms ◽

10.4324/9780203031063-7 ◽

2002 ◽

pp. 27-49

Keyword(s):

Budgetary Impact

Download Full-text

Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program

PLoS ONE ◽

10.1371/journal.pone.0213745 ◽

2019 ◽

Vol 14 (3) ◽

pp. e0213745 ◽

Cited By ~ 4

Author(s):

Eric A. Jones ◽

Benjamin P. Linas ◽

Ve Truong ◽

James F. Burgess ◽

Karen E. Lasser

Keyword(s):

Primary Care ◽

Hepatitis C ◽

Treatment Program ◽

Impact Analysis ◽

Drug Pricing ◽

Hepatitis C Treatment ◽

Budgetary Impact ◽

Program Effects

Download Full-text

PP238 Budget Impact Of Methionine-Free Amino Acid Formula For Homocystinuria

International Journal of Technology Assessment in Health Care ◽

10.1017/s0266462319002824 ◽

2019 ◽

Vol 35 (S1) ◽

pp. 75-75

Author(s):

Eduardo Mulinari ◽

Nayara Castelano Brito ◽

Lays Pires Marra

Keyword(s):

Amino Acid ◽

Free Amino Acid ◽

Free Amino ◽

Budget Impact ◽

National Committee ◽

Budgetary Impact ◽

Health Technologies ◽

Number Of Patients ◽

Wide Range ◽

Amino Acid Formula

IntroductionThe National Committee for Health Technology Incorporation (CONITEC) evaluates health technologies to recommend their inclusion or exclusion within the Brazilian Public Health System (SUS), and uses the budget impact assessment to estimate costs to the system. This study estimated the budget impact of the supply of methionine-free amino acid formula (MFAAf) for patients with classical homocystinuria (HCU) in the SUS.MethodsThe incidence of one case per 250,000 live births in Brazil and the registration of a Brazilian association of patients with HCU was assumed to calculate the population. Mortality and responsiveness to pyridoxine rates were applied. The costs of treatment were estimated according to the recommended dosage in literature and public purchasing prices. For calculating the dose of MFAAf patients, a median age of 19 years and weight of 60 kg were assumed, according to Brazilian study data.ResultsThe annual cost of treatment was estimated at BRL 77,000 (USD 21,084) per patient. The incorporation of MFAAf for HCU would generate a budget impact in SUS of around BRL 37 million (USD 10.1 million) in 2019 and BRL 188 million (USD 51.5 million) after five years which considers the epidemiological data, and a budget impact of around BRL 6.4 million (USD 1.75 million) in 2019 and BRL 33 million (USD 9 million) after five years which considers the information of a Brazilian association of patients with HCU. The wide range of values in the incremental budgetary impact is due to the lack of information on the epidemiology of the disease in Brazil.ConclusionsThe incorporation of the MFAAf in the SUS represents an important budgetary impact and covers a small number of patients. CONITEC recommended the incorporation of the MFAAf in the SUS, according to clinical protocol.

Download Full-text

PD31 Financial Impact Of Target Molecular Therapies In A Brazilian Hospital

International Journal of Technology Assessment in Health Care ◽

10.1017/s0266462318003045 ◽

2018 ◽

Vol 34 (S1) ◽

pp. 140-141

Author(s):

Maria Angélica Ferreira ◽

Caroline Lacerda ◽

Leila Moreira

Keyword(s):

New Technologies ◽

Clinical Effectiveness ◽

Drug Expenditure ◽

Financial Impact ◽

Porto Alegre ◽

Public System ◽

Budgetary Impact ◽

The Public ◽

Cost Impact ◽

Molecular Therapies

Introduction:The therapy using molecular-targeted (MTT) and monoclonal antibodies (MA) are examples of new therapeutic technologies in search of greater clinical effectiveness and reduction of adverse effects in the fight against frequent diseases. Generally, new technologies have a high cost impact on the health system. The objective of this study was to evaluate the financial impact generated by the use of MTT and MA therapies in the teaching Hospital de Clínicas, Porto Alegre, Brazil.Methods:The first 60 higher monetary spending drug items of the last 12 months were analyzed. From them, drugs which fit in the categories under study, and have been regularly used, were identified. The monthly expenditures with each item were tabulated and compared with the total expenditures on drugs, in order to calculate the budgetary impact. The major groups of diseases treated with each agent were analyzed.Results:Two MTT agents (gefitinib and infliximab) and three MAs (rituximab, basiliximab and abciximab) were identified. The highest expenditure items, respectively, per year, were the oncological medicines rituximab (USD127,890) and gefitinib (USD96,923), followed by the immunosuppressive basiliximab (USD88,998) and the immunomodulatory infliximab (USD68,642), and the platelet aggregation inhibitor abciximab (USD47,886). These values corresponding to, respectively, 1.1 percent, 0.8 percent, 0.8 percent, 0.6 percent and 0.4 percent of total drug expenditure per year (USD11,866,124). Trastuzumab, bortezomib and imatinib were often used, but directly supplied by the public system, in a way that didn't impact the hospital budgetary management.Conclusions:MTT and MA have an important impact on health budgets, and are mainly used to treat some types of cancer, cardiovascular disease and autoimmune disorders. These aspects should be considered in the management of drugs in hospitals of high complexity.

Download Full-text